Outlook Therapeutics Appoints New CMO, Director

TL;DR

Outlook Therapeutics brings in new CMO & board member, details exec pay.

AI Summary

Outlook Therapeutics, Inc. announced on December 3, 2024, the appointment of Dr. Paul Ashton as Chief Medical Officer and the election of Ms. Karen Smith to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Ashton.

Why It Matters

The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts or a strengthening of leadership within the company, potentially impacting its future drug development and business strategy.

Risk Assessment

Risk Level: medium — Changes in key leadership and executive compensation can indicate internal restructuring or strategic realignments, which carry inherent business risks.

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Registrant
• Dr. Paul Ashton (person) — Appointed Chief Medical Officer
• Ms. Karen Smith (person) — Elected to Board of Directors
• December 3, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• tm2430072d1_8k.htm (8-K) — 23KB
• 0001104659-24-125350.txt ( ) — 193KB
• otlk-20241203.xsd (EX-101.SCH) — 3KB
• otlk-20241203_lab.xml (EX-101.LAB) — 33KB
• otlk-20241203_pre.xml (EX-101.PRE) — 22KB
• tm2430072d1_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Executive Officer On December 3, 2024, C. Russell Trenary III stepped down as the President and Chief Executive Officer of Outlook Therapeutics, Inc. (the "Company") and as a member of the Company's Board of Directors (the "Board"), effective immediately (the "Effective Date"). The Board has resolved to reduce its size to nine directors immediately upon Mr. Trenary's resignation. Mr. Trenary's departure constitutes a termination of employment without "cause" for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Trenary is a party or otherwise participates, including that certain executive employment agreement, dated as of July 6, 2021, by and between Mr. Trenary and the Company (the "Employment Agreement"). Accordingly, subject to Mr. Trenary's execution and non-revocation of a separation agreement containing a release of claims against the Company, Mr. Trenary will receive severance benefits consistent with the Employment Agreement for a termination of employment without "cause." A description of Mr. Trenary's severance benefits is set forth in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on June 26, 2024, and is incorporated by reference herein. Appointment of Interim Chief Executive Officer On December 3, 2024, Lawrence A. Kenyon, 59, the Company's Chief Financial Officer, was appointed Interim Chief Executive Officer of the Company, effective as of the Effective Date, to serve while the Board conducts a formal search process to identify and appoint a permanent Chief Executive Officer. Mr. Kenyon's biographical information is set forth in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchang

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: December 4, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Interim Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR